Volume | 1,419,239 |
|
|||||
News | - | ||||||
Day High | 99.6199 | Low High |
|||||
Day Low | 97.89 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Moderna Inc | MRNA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
98.57 | 97.89 | 99.6199 | 98.17 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
23,036 | 1,419,239 | $ 98.75 | $ 140,150,243 | - | 95.02 - 217.25 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:48:12 | 100 | $ 99.525 | USD |
Moderna (MRNA) Options Flow Summary
Moderna Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
37.88B | 380.59M | - | 19.26B | 8.36B | 21.97 | 4.53 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Moderna News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRNA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 102.31 | 107.79 | 97.11 | 102.16 | 3,078,729 | -2.79 | -2.72% |
1 Month | 113.75 | 118.07 | 97.11 | 108.41 | 3,863,298 | -14.23 | -12.51% |
3 Months | 122.89 | 128.98 | 95.02 | 111.59 | 3,984,493 | -23.37 | -19.01% |
6 Months | 149.80 | 163.24 | 95.02 | 123.06 | 3,585,215 | -50.28 | -33.56% |
1 Year | 123.34 | 217.25 | 95.02 | 147.16 | 4,102,459 | -23.82 | -19.31% |
3 Years | 69.53 | 497.17 | 65.4899 | 202.48 | 9,099,110 | 30.00 | 43.14% |
5 Years | 22.00 | 497.17 | 11.54 | 149.36 | 8,743,396 | 77.53 | 352.39% |
Moderna Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |